TARA (Protara Therapeutics) Other Current Liabilities: $1.09 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TARA Protara Therapeutics Inc TARA
32 GF Score
Price $3.93
! 3 Warning Signs
View Full Analysis

What is Protara Therapeutics Other Current Liabilities?

Protara Therapeutics TARA -2.73% 32 Other Current Liabilities is $1.09 Mil as of Mar. 2026. GuruFocus rates TARA with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Protara Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $1.09 Mil.

Protara Therapeutics's quarterly other current liabilities increased from Sep. 2025 ($2.24 Mil) to Dec. 2025 ($3.27 Mil) but then declined from Dec. 2025 ($3.27 Mil) to Mar. 2026 ($1.09 Mil).

Protara Therapeutics's annual other current liabilities increased from Dec. 2023 ($2.11 Mil) to Dec. 2024 ($2.53 Mil) and increased from Dec. 2024 ($2.53 Mil) to Dec. 2025 ($3.27 Mil).

Protara Therapeutics Other Current Liabilities Related Terms

Protara Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Protara Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protara Therapeutics Other Current Liabilities Chart

Protara Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 1.80 2.54 2.11 2.53 3.27

Protara Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 1.48 2.24 3.27 1.09
TARA
32GF Score
Protara Therapeutics Inc TARA
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protara Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $1.09 Mil mean?
Protara Therapeutics (TARA) has a Other Current Liabilities of $1.09 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Protara Therapeutics.
Is Protara Therapeutics' Other Current Liabilities too high?
Protara Therapeutics' current Other Current Liabilities is $1.09 Mil. Overall, Protara Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Protara Therapeutics' Other Current Liabilities compare to TRDA and ACIU?
Protara Therapeutics' Other Current Liabilities of $1.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Protara Therapeutics. Protara Therapeutics's current Other Current Liabilities is $1.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protara Therapeutics stock overvalued right now?
Protara Therapeutics (TARA) has a current Other Current Liabilities of $1.09 Mil. The current Other Current Liabilities is $1.09 Mil. Protara Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Protara Therapeutics (TARA), the current Other Current Liabilities is $1.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protara Therapeutics Business Description

Other Exchanges 1KPA:Germany
Address 345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
32GF Score

Get the complete analysis for TARA

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.93
Price